Parenteral Nutrition Market (2033): Amino Acids, Lipid Emulsions & Hospital Nutrition Growth in United States Expansion

DataM Intelligence has released a new research report titled "Parenteral Nutrition Market Size 2026". The report provides in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, competitive landscape, and the performance of leading industry players. It also highlights major growth drivers shaping the global parenteral nutrition market, with detailed analysis of emerging opportunities and future development prospects.

Download Sample Report (Get Higher Priority for Corporate Email ID):-
https://www.datamintelligence.com/download-sample/parenteral-nutrition-market?sindhuri

Strategic Insights
• The global Parenteral Nutrition Market was valued at approximately USD 8.02 billion in 2025 and is projected to reach around USD 12.72 billion by 2033, expanding at a CAGR of 5.8% during 2026-2033.
• The increasing prevalence of chronic diseases, including cancer, along with critical illnesses and conditions that limit oral or enteral nutrition, is strengthening demand for parenteral nutrition therapies that deliver essential amino acids, lipids, vitamins, minerals, electrolytes, and trace elements directly into the bloodstream.
• Amino acids represented a major market segment, supported by growing cases of renal and hepatic insufficiency and protein-catabolic critical illnesses. Parenteral lipid emulsions are also expected to expand significantly, particularly because of their role as an energy source and supply of essential fatty acids in pediatric and critically ill patients.
• North America currently holds the largest regional share, supported by advanced healthcare infrastructure, greater awareness of parenteral nutrition, chronic disease prevalence, healthcare spending, and favorable reimbursement policies. Asia-Pacific is projected to be the fastest-growing region, driven by rising malnutrition risks, growing awareness, population growth, and modernization of healthcare infrastructure in countries such as China and India.
• Key companies operating in the market include Sichuan Kelun Pharmaceutical Co., Ltd., Fresenius Kabi AG, Grifols S.A., Baxter International, Inc., B. Braun Melsungen AG, Pfizer Inc., Claris Lifesciences Limited, and Allergan plc (Actavis plc). Product launches, collaborations, manufacturing expansion, and product agreements remain important competitive strategies.
• Recent industry activity is increasingly focused on advanced lipid emulsions, multi-chamber infusion bags, all-in-one formulations, micronutrient stability, pediatric and neonatal nutrition, sterile compounding, and infusion safety, supporting safer and more efficient clinical nutrition delivery.

United States: Recent Industry Developments
✅ April 2026: Baxter continued advancing clinical nutrition solutions in the U.S., supporting individualized parenteral nutrition through automated compounding technologies, multi-chamber formulations, and nutrition monitoring solutions.
✅ February 2026: ICU Medical reported continued expansion of its infusion-therapy portfolio and highlighted its parenteral nutrition pharmacy-preparation business as part of its 2026 growth strategy.
✅ January 2026: B. Braun continued strengthening its U.S. parenteral nutrition portfolio, including amino-acid solutions, lipid emulsions, and compounding technologies designed to support customized nutritional therapy.
✅ December 2025: U.S. clinical nutrition providers increasingly emphasized automated compounding, customized formulations, and pharmacy workflow technologies to improve the safety, consistency, and efficiency of parenteral nutrition delivery.

Parenteral Nutrition Market - Key Players, Company Evaluation & Growth Forecast 2026
List of Key Players 2026:
Baxter International Inc., Otsuka Pharmaceutical Factory, Inc., Fresenius Kabi AG, B. Braun Melsungen AG, Grifols S.A., Sichuan Kelun Pharmaceutical Co., Ltd., Pfizer Inc., ICU Medical, Inc., JW Pharmaceutical, and Aculife Healthcare Pvt. Ltd.

Company Evaluation
Leading healthcare and clinical nutrition companies such as Baxter International, Fresenius Kabi, B. Braun, and Grifols are strengthening their positions through advanced parenteral nutrition formulations, lipid emulsions, amino-acid solutions, infusion technologies, and multi-chamber bag systems. Their established manufacturing capabilities, hospital relationships, and broad product portfolios provide strong competitive advantages.

Innovative and regional players such as Sichuan Kelun Pharmaceutical, JW Pharmaceutical, and Aculife Healthcare are expanding production capacity and developing cost-effective parenteral nutrition solutions, particularly across emerging healthcare markets. Product innovation, sterile manufacturing capabilities, regulatory compliance, and the ability to address pediatric and critical-care nutritional requirements remain key areas of evaluation.

Growth Forecast Projected 2026:
The Global Parenteral Nutrition Market was estimated at approximately USD 8.02 billion in 2025 and is projected to reach around USD 12.72 billion by 2033, growing at a CAGR of 5.8% during 2026-2033. The market is expected to expand steadily, supported by increasing chronic diseases, critical-care requirements, pediatric nutritional needs, rising malnutrition awareness, and continued development of advanced parenteral nutrition formulations and delivery systems. Asia-Pacific is identified as the fastest-growing region, while North America remains the largest regional market.

Get a Customized Industry Report:
https://www.datamintelligence.com/customize/parenteral-nutrition-market?sindhuri

Key Developments 2025-2026:
✅ May 2026: Baxter International expanded its global parenteral nutrition portfolio with advanced lipid emulsion and multi-chamber bag solutions aimed at improving patient safety and reducing infection risks in critical-care settings.
✅ April 2026: Fresenius Kabi strengthened its clinical nutrition manufacturing capacity across Europe and Asia to meet rising demand for hospital-based parenteral nutrition therapies.
✅ March 2026: B. Braun introduced enhanced all-in-one parenteral nutrition formulations designed to improve micronutrient stability and extend shelf life for intensive-care applications.
✅ February 2026: Otsuka Pharmaceutical advanced research into pediatric and neonatal parenteral nutrition solutions, focusing on precision electrolyte balance and improved metabolic outcomes.
✅ January 2026: Pfizer expanded hospital nutrition collaborations supporting critical-care parenteral feeding protocols for oncology and post-surgical recovery patients.
✅ December 2025: Grifols enhanced sterile compounding and infusion-safety systems to support large-scale parenteral nutrition preparation in hospital pharmacies.
✅ November 2025: Sichuan Kelun Pharmaceutical increased production of parenteral nutrition infusion bags to support growing demand across Asia-Pacific healthcare facilities.

How Our Market Research Process Works:
The global Parenteral Nutrition Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates key industry-influencing factors, including the rising prevalence of chronic diseases, increasing cases of malnutrition, pediatric and neonatal nutritional requirements, healthcare infrastructure development, regulatory frameworks, and evolving clinical nutrition practices. It also analyzes technological advancements in lipid emulsions, amino acid formulations, multi-chamber bags, sterile compounding, and all-in-one parenteral nutrition solutions.

In addition, the report assesses competitive intensity, product launches, collaborations, manufacturing expansions, mergers and acquisitions, pricing trends, supply-chain dynamics, market opportunities, regulatory challenges, and emerging innovations shaping the future of the parenteral nutrition ecosystem.

Recent Mergers & Acquisitions (M & A) 2025-2026:
• May 2025: Otsuka Pharmaceutical Factory America acquired a 60% interest in the IV solution business of ICU Medical, establishing Otsuka ICU Medical LLC as a subsidiary. The transaction strengthens Otsuka's IV-solution manufacturing and distribution capabilities in North America and creates opportunities to expand the supply of nutritional IV solutions globally.
• March 2026: Otsuka Pharmaceutical announced an agreement to acquire Transcend Therapeutics for an upfront consideration of US$700 million, with potential additional milestone payments. While focused on neuropsychiatric therapies rather than parenteral nutrition, the transaction reflects Otsuka's broader strategy of expanding its healthcare portfolio and development capabilities.
• June 2026: Otsuka completed the acquisition of Transcend Therapeutics, with Transcend becoming a wholly owned subsidiary of Otsuka America. The deal further expands Otsuka's international healthcare platform.
• 2025-2026: Strategic expansion across clinical nutrition and IV therapy continued as major manufacturers focused on strengthening manufacturing capacity, product portfolios, distribution networks, and access to specialized nutrition therapies. Fresenius Kabi, Baxter, B. Braun and Otsuka remain among the major companies active across the parenteral nutrition landscape.

Japan: Recent Industry Developments
✅ June 2026: Otsuka Pharmaceutical Factory continued strengthening its clinical nutrition portfolio following the expansion of its IV-solutions business in North America, supporting opportunities for nutritional IV solutions and global supply development.
✅ 2026: Clinical research in Japan advanced evaluation of a novel total parenteral nutrition formula for patients with chronic kidney disease, with a multicenter randomized Phase III study examining vitamin profiles and nutritional outcomes.
✅ November 2025: Otsuka Pharmaceutical entered a joint research agreement with Japan's National Cerebral and Cardiovascular Center to evaluate nutrition-monitoring technologies for cardiovascular patients, highlighting the growing role of personalized nutrition and digital health in clinical care.
✅ December 2024: Otsuka Pharmaceutical Factory launched KIDPAREN Injection, a three-chamber total parenteral nutrition formulation containing amino acids, glucose, electrolytes, fats and vitamins, specifically designed for high-calorie parenteral nutrition in patients with chronic kidney disease requiring fluid restriction.

Market Outlook
The global Parenteral Nutrition Market is being supported by increasing demand for specialized nutritional therapies, rising prevalence of chronic diseases, growing numbers of patients requiring intravenous nutrition, and continued innovation in ready-to-use multi-chamber bags and patient-specific formulations. Major companies are increasingly emphasizing product innovation, supply-chain reliability and geographic expansion.
Fresenius Kabi, Baxter, B. Braun, Otsuka Pharmaceutical Factory, ICU Medical, Grifols and other established players remain important participants in the competitive landscape.

Unlock & Gain Complete 360° Market Visibility:
https://www.datamintelligence.com/buy-now-page?report=parenteral-nutrition-market?sindhuri

Segments Covered in the Global Parenteral Nutrition Market
By Type
The market is segmented into amino acids, trace elements, parenteral lipid emulsions, vitamins, electrolytes & minerals, and others (includes fats). Amino acids dominate the market due to their essential role in providing protein and nitrogen for patients who cannot receive adequate nutrition through the gastrointestinal tract. Parenteral lipid emulsions are witnessing strong growth driven by their role as a concentrated energy source and increasing use in critically ill and nutritionally compromised patients. Electrolytes & minerals, vitamins, and trace elements are increasingly used to maintain essential physiological functions, while other products such as fats serve specialized nutritional requirements.

By End-User
The market is divided into hospitals (60%), clinics (15%), homecare (18%), and others (7%). Hospitals lead the segment due to the high number of critically ill, surgical, oncology, and intensive-care patients requiring specialized nutritional support. Homecare is witnessing significant growth with the increasing adoption of home parenteral nutrition for patients requiring long-term nutritional therapy. Clinics are also expanding steadily as outpatient and specialized nutritional care services become more accessible, while other end users serve specific patient-care and institutional requirements.

By Region
North America - 35% Share
North America leads the market due to the high prevalence of chronic and critical illnesses, advanced healthcare infrastructure, strong adoption of nutritional therapies, and increasing demand for home parenteral nutrition across the United States and Canada.

Europe - 28% Share
Europe is driven by well-established healthcare systems, rising incidence of chronic diseases, increasing numbers of surgical and critically ill patients, and growing adoption of home-based nutritional support, particularly across countries such as Germany, France, the UK, and Italy.

Asia-Pacific - 23% Share
Asia-Pacific is expanding rapidly due to improving healthcare infrastructure, rising healthcare expenditure, increasing prevalence of chronic and acute diseases, and growing awareness of clinical nutrition therapies across China, Japan, India, South Korea, and other emerging markets.

People Also Ask:
1.What are the major factors driving the growth of the parenteral nutrition market?
A: Increasing chronic diseases such as cancer, rising pediatric nutritional disorders, growing cases of malnutrition, and increasing demand for specialized nutritional support are major factors driving market growth.

2.What are the major types of parenteral nutrition products?
A: The market is segmented into amino acids, trace elements, parenteral lipid emulsions, vitamins, electrolytes and minerals, and other products including fats.

3.What factors are increasing demand for parenteral nutrition in pediatric patients?
A: Pediatric disorders, nutritional deficiencies, and the need for controlled nutrient delivery are increasing demand for specialized parenteral nutrition. Lipid emulsions are particularly relevant because they provide essential fatty acids and a concentrated energy source.

4.How does the increasing prevalence of cancer affect the parenteral nutrition market?
A: Cancer and its associated treatment-related nutritional challenges can increase the need for nutritional support. As the global cancer burden rises, demand for parenteral nutrition products is expected to increase, particularly in hospital and critical-care settings.

Contact Us -
Company Name: DataM Intelligence Contact
Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.